News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ipsen In-Licenses from PhotoCure Hexvix(R), the First Approved & Marketed Drug for Improved Detection of Bladder Cancer, a Key Step in the Surgical Resection



9/27/2011 6:46:22 AM

PARIS--(BUSINESS WIRE)--Regulatory News: Ipsen (Paris:IPN) (Euronext: IPN, ADR: IPSEY) announces today a partnership with Photocure (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in cancer and dermatology. Photocure has entered into a strategic collaboration with Ipsen to commercialise Hexvix®, its flagship product for the diagnosis and resection of bladder cancer, worldwide except in the United States of America (USA) and the Nordic region.

Read at BioSpace.com

Related News

comments powered by Disqus
PhotoCure
Ipsen
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES